MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum

Breast Cancer Clinical Trial

Official title:

Improving Exercise Capacity With a Tailored Physical Activity Intervention in Lymphoma and Breast Cancer Patients Undergoing Treatment - An Addendum to NIH R01CA167821 "Early Imaging Detection of Cardiovascular Injury After Cancer"

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01719562
• Other study ID #: IRB00020968
• Secondary ID: NCI-2012-01613P3
• Status: Completed
• Phase: N/A
• Start date: January 1, 2013
• Est. completion date: March 8, 2022

Study information

• Verified date: May 2023
• Source: Wake Forest University Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial studies how well magnetic resonance imaging (MRI) works in detecting heart damage in patients with cancer receiving chemotherapy. Diagnostic procedures, such as MRI, may help doctors predict whether patients will have heart damage caused by chemotherapy in patients with cancer receiving chemotherapy.

Exercise Capacity Addendum Brief Summary: This study is designed to demonstrate feasibility of performing the physical activity intervention and the primary outcome measures before, during and six months after initiating Anth-bC for treatment of non- or Hodgkin lymphoma. This study will test the potential for a novel (lifestyle) intervention designed to improve exercise capacity, health-related quality of life and cardiac and cognitive dysfunction. This data will inform the development of the R33 phase of the clinical trial to determine if the physical activity intervention can reduce exercise intolerance in this high-risk population. In addition, cardiac MRI data from individuals within this pilot will be compared to cardiac MRI data from individuals in the parent study that did not undergo either of the two interventional arms of this study.

Description:

PRIMARY OBJECTIVES:

I. To design an automated MRI hardware/software platform for measuring and reporting left ventricular (LV) function (volumes, strain, and ejection fraction [EF]), T1 myocardial signal, and aortic pulse wave velocity (PWV).

II. To determine if pre- to 3 month post-anthracycline-based chemotherapy (Anth-bC) changes in our MRI platform generated measures of LV volumes, EF, strain, myocardial T1, and aortic PWV predict pre- to 24 month post-Anth-bC differences in these same parameters.

OUTLINE:

Patients undergo MRI scans for LV function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months.

Exercise Capacity Addendum Objectives:

Primary Objective:

• To provide critical participant enrollment data necessary to accomplish the R01 submission, including:

• Feasibility of screening, enrolling, and randomizing 21 Non or Hodgkin lymphoma and stage I-IV breast cancer patients including the reasons for failed randomization,

• Identification of barriers for participating in, or adhering to the Patient ES-AI and the Healthy Living Control Group.

Secondary Objective:

• In these 21 patients, at study initiation then 3 and 6 months after initiating Anth-bC or other potentially cardiotoxic cancer therapies, to assess the ability to ascertain: peak exercise cardiac output, calculated arteriovenous oxygen difference (A-V O2) and VO2 (maximum rate of oxygen), and pre-exercise measures of left ventricular and cognitive function, health-related quality of life, six-minute walk distance (6min WD) and fatigue. Ascertainment of the left ventricular function and health-related rate quality of life will be attempted in a manner similar to ascertainment of these variables from 47 individuals with lymphoma in the parent study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: March 8, 2022
• Est. primary completion date: March 8, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

PARENT STUDY:

Inclusion Criteria:

• Receiving >= 350 mg/m^2 of Anth-bC therapy, or a combination of Anth-bC (>= 250 mg/m^2) and subsequent paclitaxel or Herceptin

• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Intracranial metal, pacemakers, defibrillators, functioning neurostimulator devices, or other implanted electronic devices

• Ferromagnetic cerebral aneurysm clips, or other intraorbital/intracranial metal

• Allergy to gadolinium or other severe drug allergies

• Unstable angina

• Significant ventricular arrhythmias (> 20 premature ventricular contractions [PVCs]/minute due to gating difficulty)

• Acute myocardial infarction within 28 days

• Atrial fibrillation with uncontrolled ventricular response

• Moderate or severe aortic stenosis

• Claustrophobia

• Congestive heart failure (New York Heart Association [NYHA] class III or IV)

• Significant valvular disease, or significant pulmonary disease requiring supplemental oxygen therapy

• Participants unwilling to complete the protocol (24 month duration)

• Women who are pregnant

• Patients unable or unwilling to provide informed consent

EXERCISE CAPACITY ADDENDUM:

Inclusion Criteria:

• Men and women aged 18-85 with non- or Hodgkin lymphoma or I-IV stage breast cancer patients that expect to receive an anthracycline based chemotherapeutic regimen or other potentially cardiotoxic cancer therapies (e.g. chemotherapy regimens [anthracyclines, trastuzumab]), immuno-therapies (immune checkpoint inhibitors [ICI's]) or radiation (within 8 weeks of completion).

• Potential enrollees will need the capacity to walk at least two (2) city blocks on a flat surface.

• English speaking participants only will be enrolled.

• Stage IV breast cancer participants must have a 2 year survival prognosis and approval from their physician.

Exclusion Criteria: The following are relative contraindications and can be considered by the medical director of the study:

• Uncontrolled hypertension (systolic blood pressure >190 mm Hg or diastolic blood pressure >100 mm Hg)

• A recent history of alcohol or drug abuse.

• Inflammatory conditions such as lupus or inflammatory bowel disease, or another medical condition that might compromise safety or successful completion.

• Other exclusions include those with contraindications to MRI such as ferromagnetic cerebral aneurysm clips or other intracranial metal, pacemakers, defibrillators, functioning neurostimulator devices or other implanted electronic devices.

• Unstable angina.

• Inability to exercise on a treadmill or stationary cycle.

• Significant ventricular arrhythmias (>20 PVCs/min due to gating difficulty).

• Atrial fibrillation with uncontrolled ventricular response.

• Acute myocardial infarction within 28 days.

• Moving within 12 months of enrollment.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Cardiac Toxicity
• Cardiotoxicity
• Malignant Neoplasm
• Neoplasms

Intervention

Procedure:
• Magnetic resonance imaging
Patients undergo MRI scans for left ventricular function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months.

Other:
• Physical Activity
Tailored aerobic exercise program onsite and at home.
• Healthy Living
Healthy living presentations at a centralized meeting place and over the phone.

Device:
• Cardiopulmonary Exercise Testing (CPET)
Performed on the treadmill using the Bruce or Modified Bruce protocol based on current fitness level.

Other:
• Questionnaire Administration
A self-administered 13-item scale to assess fatigue in participants

Locations

Country	Name	City	State
United States	Virginia Commonwealth University Health Sciences	Richmond	Virginia
United States	Comprehensive Cancer Center of Wake Forest University	Winston-Salem	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Wake Forest University Health Sciences	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Completing the Trial (Exercise Capacity Addendum)	The number of participants who completed the intervention.	6 months after treatment initiation
Primary	Number of Participants Able to Complete Assessments (Exercise Capacity Addendum)	Number of participants who completed the 6-minute walk test at 6-months.	6 months after treatment initiation
Secondary	Peak Exercise Cardiac Output (Exercise Capacity Addendum)	Peak exercise cardiac output refers to the amount of blood that the heart pumps out per minute. It is an important measure of how effectively the heart is working to deliver oxygen and nutrients to the body's tissues. Peak exercise cardiac output was measured in a cardiac magnetic resonance imaging (MRI) exam.	6 months after treatment
Secondary	Arteriovenous Oxygen Difference (A-V O2) (Exercise Capacity Addendum)	Arteriovenous Oxygen Difference (A-V O2) is the difference in oxygen levels between arterial blood and venous blood. A-V O2 difference is important because it reflects how much oxygen is being used by the body's tissues during exercise or physical activity. A higher A-V O2 difference is generally considered better.	6 months after treatment initiation
Secondary	Maximum Rate of Oxygen Consumption (VO2) (Exercise Capacity Addendum)	Maximum rate of oxygen consumption (VO2) is an objective measure of cardiorespiratory fitness. VO2 was assessed with a cardiopulmonary exercise test (CPET). Higher VO2 represents greater cardiorespiratory fitness.	6 months after treatment initiation
Secondary	Left Ventricular Function (Exercise Capacity Addendum)	Left ventricular ejection fraction (LVEF, %) is a measure of cardiac function. LVEF was assessed with a cardiac magnetic resonance imaging (MRI) exam. The higher the LVEF, the more efficiently the heart is at pumping blood to the rest of the body with every heart beat.	6 months after treatment initiation
Secondary	Cognitive Function- Controlled Oral Word Association (COWA) Test (Exercise Capacity Addendum)	The COWA test was used to assess cognitive function and verbal fluency. Participants were asked to produce as many words as they can that begin with the given letter (i.e. T or L) within a 1-min time period. The COWA test total score was measured by summing the total number of acceptable words produced for three different letters. Minimum possible score for the COWA text is 0. There is no maximum possible score. Higher scores represent greater verbal fluency.	6 months after treatment initiation
Secondary	Health-Related Quality of Life (Exercise Capacity Addendum)	The Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) is a 42-item scale used to assess the health-related quality of life of lymphoma survivors. The FACT-Lym questionnaire examines the four primary domains of HRQL: physical, social, emotional, and functional well-being, and patient's concerns related to lymphoma. The FACT-Lym was examined as a total score, ranging from 0 to 168 points. Higher scores reflect better health-related quality of life.	6 months after treatment initiation
Secondary	6-minute Walk Distance (Exercise Capacity Addendum)	The 6-minute walk test is a low cost sub-maximal exercise test that serves as an indirect measure of cardiorespiratory fitness. Participants were instructed to walk at their own pace to cover as much ground (in meters) as possible for 6 minutes.	6 months after treatment initiation
Secondary	Functional Assessment of Cancer Therapy - (FACT-Fatigue) (Exercise Capacity Addendum)	The FACT-fatigue is a 13-item scale that has been widely used to assess cancer-related fatigue. The FACT-fatigue questionnaire was scored by summing all 13 items with a reverse point system. This produces a range of 0 to 52, with a higher score indicating better functioning and less fatigue.	6 months after treatment initiation